HCPCS code J9350: Mosunetuzumab injection, per 1 mg2026 Medicare rate & RVUs in Illinois
Mosunetuzumab-axgb is an intravenous bispecific antibody used for certain adults with relapsed or refractory follicular lymphoma after prior systemic treatment.
CMS doesn’t publish an office rate for J9350 in Illinois.
Medicare allowed amount for participating (non-QP) physicians, before deductible, coinsurance and claim adjustments. Not a patient’s bill or a hospital charge.
Your location
On this page 9 sections
What J9350 covers
Mosunetuzumab-axgb is an intravenous bispecific antibody that links CD20-positive B cells with CD3-positive T cells. It is used for adults with relapsed or refractory follicular lymphoma after at least two prior systemic therapies. Oncology clinicians administer it by infusion, using step-up dosing and monitoring for reactions such as cytokine release syndrome and neurologic toxicity.
J9350 identifies the drug quantity, not the infusion service. Each billing unit represents 1 mg of mosunetuzumab-axgb, so units are based on the administered dose. CMS assigns physician fee schedule status E, excluding the code from that schedule; when Medicare covers the drug, payment is under another method. CMS classifies it as a Part B drug, generally priced from quarterly Average Sales Price files when covered. The Medicare contractor determines coverage.
This summary was written with AI assistance from CMS physician fee schedule data and checked against the CMS billing rules shown here. Rates on this page come directly from CMS files.
Where J9350 pays more and less in Illinois
The same RVUs, adjusted for each area’s costs. Open a locality for its calculation, history and nearby areas.
| Payment locality | Office | Facility |
|---|---|---|
| Chicago, IL | Unavailable | Unavailable |
| East St. Louis, IL | Unavailable | Unavailable |
| Rest of Illinois | Unavailable | Unavailable |
| Suburban Chicago, IL | Unavailable | Unavailable |
How the J9350 rate is calculated
Each of J9350’s three RVUs is multiplied by a geographic index (GPCI) for the payment locality, added up, and multiplied by the conversion factor. Drag the indexes or enter a ZIP to see what moves the rate.
How the rate is built · J9350
RVUs × geographic indexes × conversion factor
Work0.00
0.00 RVUs× 1.000 GPCI
Practice expense0.00
0.00 RVUs× 1.000 GPCI
Malpractice0.00
0.00 RVUs× 1.000 GPCI
Adjusted RVUs
0.0000
Conversion factor
$33.4009
Medicare rate
$0.00
Every GPCI starts at 1.000, the national rate. Enter a ZIP or drag a slider.
Payment rules and modifiers for J9350
J9350 has no global surgery period, no multiple-procedure, bilateral or assistant-at-surgery adjustment, and no professional/technical split. What changes the payment is where the service happens: the place of service on the claim decides whether Medicare pays the office or the facility rate.
Place of service · J9350
Which rate does Medicare pay?
The POS code on the claim line (CMS-1500 box 24B).
POS 11 · non-facility rate · national
—
J9350 isn’t priced in this setting.
J9350 compared with similar codes
Compare codes · National
4 codes, side by side
How to choose
- J9312Rituximab injectionPer 10 mg
- J9312 identifies rituximab, not mosunetuzumab-axgb. Choose based on the drug administered; their billing units represent different quantities.
- J9301ObinutuzumabPer 10 mg
- J9301 identifies obinutuzumab, a different anti-CD20 drug. It is not the code for mosunetuzumab-axgb.
- J9311Rituximab-hyaluronidasePer 10 mg
- J9311 identifies a subcutaneous rituximab-hyaluronidase product. J9350 is for intravenous mosunetuzumab-axgb.
J9350 billing questions
How many units should be reported?
Each J9350 unit represents 1 mg of mosunetuzumab-axgb. Calculate units from the amount administered.
How is J9350 different from J9312?
J9350 represents mosunetuzumab-axgb; J9312 represents rituximab. Select the code for the drug actually administered.
Does J9350 include the infusion service?
No. J9350 identifies the drug quantity; report the infusion service separately using the appropriate administration code.
How does Medicare treat this code?
CMS assigns status E, excluding J9350 from the physician fee schedule. When covered, it is treated as a Part B drug and generally priced from quarterly ASP files.
Does J9350 establish Medicare coverage?
No. Coverage is determined by the Medicare contractor.
Where these rates come from
FeeBase calculates base physician payments from CMS work, practice-expense and malpractice RVUs, adjusted by each locality’s geographic indexes and the conversion factor. Services without a published rate are labeled, never given a made-up amount. Amounts are Medicare allowed amounts before claim adjustments: not a patient’s bill or a commercial rate.
CMS RVU26D · effective Oct 1, 2026 through the day before Jan 1, 2027
Fee sheets · Coming soon
Put J9350 and the rest of your codes on one sheet
Your codes at your locality, with payer contracts beside Medicare.
Join the waitlist